PCM
ELDN icon

Prelude Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Prelude Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-36,141
Closed -$97.9K – 1214
2025
Q2 		$97.9K Sell
36,141
-3,230
-8% -$9.69K 0.01% 920
2025
Q1 		$133K Sell
39,371
-35,205
-47% -$145K 0.01% 1008
2024
Q4 		$307K Buy
+74,576
New +$294K 0.02% 794
2020
Q4 		– Sell
-1,127
Closed -$19K – 1460
2020
Q3 		$19K Buy
+1,127
New +$11.1K ﹤0.01% 1333

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Prelude Capital Management's ELDN Position: Q3 2025 in Review

Prelude Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q3 2025, closing a stake of 36,141 shares — an estimated $97.9K sold.

Prelude Capital Management first reported a position in ELDN in Q3 2020 and held it in 4 quarters. The position peaked at $307K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q3 2025.

  • Prelude Capital Management reported no remaining Eledon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 36,141 Eledon Pharmaceuticals shares in Q3 2025, an estimated $97.9K.
  • Prelude Capital Management first reported a position in Eledon Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Prelude Capital Management's Eledon Pharmaceuticals position peaked at $307K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.